Climb Bio (CLYM) Depreciation & Amortization (CF) (2025 - 2026)
Climb Bio (CLYM) posted Depreciation & Amortization (CF) of $38000.0 for Q1 2026, up 26.67% on a QoQ basis from $30000.0 in Q4 2025.
Climb Bio (CLYM) Depreciation & Amortization (CF) (2025 - 2026) Analysis & Trends
Climb Bio's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $38000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $38000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135000.0 (changed N/A YoY) and the FY2025 annual result came in at $97000.0, changed N/A from the prior year.
- Depreciation & Amortization (CF) was $38000.0 for Q1 2026 at Climb Bio, up from $30000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $38000.0 in Q2 2025 and bottomed at $29000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | 38,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38,000.00 |
| Mar 31, 2026 | 38,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Jun 30, 2025 | 38,000.00 |